abstract |
Provided in the present invention are an aberrant glycosylation integrin, AG-αβ1, and a use thereof as a bladder cancer marker. Also provided in the present invention are an anti-AG-αβ1 hybridoma monoclonal antibody, a monoclonal antibody BCMabl as a secretion thereof, and a use of BCMabl in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is a use of an inhibitor of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of the medicament for the treatment of bladder cancer. |